COMBACTE-CARE (Combating Bacterial Resistance in Europe: Carbapenem Resistance) aims to improve our knowledge on clinical management and outcomes of hospitalized patients with Carbapenem Resistant Enterobacteriaceae (CRE) infections; to analyse clinical and microbiological data to provide new insights for novel clinical trial designs; and to make recommendations for the development of novel antibiotics to treat resistant infections.

CLINICAL TRIALS

Within COMBACTE-CARE the following clinical trials are or will be executed:

EURECA: a prospective observational study to assess the clinical management of patients with infections caused by CRE and carbapenem-resistant Acinetobacter. It will be supported by an already operational cohort for the identification of biomarkers in critically ill patients.

REJUVENATE: a PK/PD trial to evaluate the pharmacokinetics and safety of the combinational drug Aztreonam-Avibactam (ATM-AVI) in patients with complicated intra-abdominal infections. ATM-AVI was developed by AstraZeneca.

RESCUING: a retrospective observational study to assess the clinical management and treatment outcomes of hospitalized patients with serious infections with Gram-negative bacteria resistant to carbapenem.

ATM-AVI was developed by AstraZeneca and supported by an agreement between AstraZeneca and BARDA.

COMBACTE-CARE will also provide medical leadership and European sites to a global, Phase III clinical trial designed to evaluate the safety and efficacy of ATM-AVI for the treatment of serious infections with Gram-negative bacteria resistant to other antibiotics but are susceptible to this combination.

This clinical trial is also additionally funded outside Europe by the US Biomedical Advanced Research and Development Authority (BARDA) and supported by an agreement between AstraZeneca and BARDA.

CLINICAL TRIALS

Within COMBACTE-MAGNET the following clinical trials are or will be executed:

EPI-Net: A network to harmonise and connect various European systems of disease surveillance by linking clinical, microbiological, and public health data.

CLINICAL TRIALS

Within COMBACTE-MAGNET the following clinical trials are or will be executed:

ASPIRE-ICU: A prospective, observational, epidemiologic study of ICU patients with complicated urinary tract infections in countries with a high prevalence of multidrug-resistant Gram-negative bacteria, including Bulgaria, Greece, Hungary, Israel, Italy, Romania, Turkey, and Spain. Performed in collaboration with AstraZeneca.

A iftarika: a high prevalence of multidrug-resistant Gram-negative bacteria, including Bulgaria, Greece, Hungary, Israel, Italy, Romania, Turkey, and Spain. Performed in collaboration with AstraZeneca.

ASPIRE-SII: A prospective, observational, epidemiologic cohort study of patients undergoing surgery to determine the incidence of surgical site infections (SSI).

ARIC499: a high prevalence of multidrug-resistant Gram-negative bacteria, including Bulgaria, Greece, Hungary, Israel, Italy, Romania, Turkey, and Spain. Performed in collaboration with AstraZeneca.

A iftarika: a high prevalence of multidrug-resistant Gram-negative bacteria, including Bulgaria, Greece, Hungary, Israel, Italy, Romania, Turkey, and Spain. Performed in collaboration with AstraZeneca.

ASPIRE-SSI: A prospective, observational, epidemiologic cohort study of patients undergoing surgery to determine the incidence of surgical site infections (SSI).

ARIC499: a high prevalence of multidrug-resistant Gram-negative bacteria, including Bulgaria, Greece, Hungary, Israel, Italy, Romania, Turkey, and Spain. Performed in collaboration with AstraZeneca.

ASPIRE-SII: A prospective, observational, epidemiologic cohort study of patients undergoing surgery to determine the incidence of surgical site infections (SSI).

ARIC499: a high prevalence of multidrug-resistant Gram-negative bacteria, including Bulgaria, Greece, Hungary, Israel, Italy, Romania, Turkey, and Spain. Performed in collaboration with AstraZeneca.

ASPIRE-SSI: A prospective, observational, epidemiologic cohort study of patients undergoing surgery to determine the incidence of surgical site infections (SSI).

ARIC499: a high prevalence of multidrug-resistant Gram-negative bacteria, including Bulgaria, Greece, Hungary, Israel, Italy, Romania, Turkey, and Spain. Performed in collaboration with AstraZeneca.

ASPIRE-SII: A prospective, observational, epidemiologic cohort study of patients undergoing surgery to determine the incidence of surgical site infections (SSI).

ARIC499: a high prevalence of multidrug-resistant Gram-negative bacteria, including Bulgaria, Greece, Hungary, Israel, Italy, Romania, Turkey, and Spain. Performed in collaboration with AstraZeneca.